Drug Trial Radar · NCT07428759
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
122
Actual
Start
Mar 10, 2026
Primary completion
Nov 19, 2026
Study completion Nov 19, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months. The study aims to determine if PnMAPS30plus is safe and well-tolerated and whether it helps the body produce antibodies that protect against pneumococcal disease.
Conditions
- Pneumonia, Bacterial
Interventions
Pn-MAPS30plusBiological
Single dose of Pn-MAPS30plus received intramuscularly.
PCV20Combination product
Single dose of PCV20 received intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Solicited Administration Site Adverse Events (AEs)Time frame: Day 1 to Day 7
- Number of Participants with Solicited Systemic AEsTime frame: Day 1 to Day 7
- Number of Participants with Unsolicited AEsTime frame: Day 1 to Day 30
- Number of Participants with Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 181 (study end)
- Number of Participants with Adverse Events of Special Interest (AESIs)Time frame: From Day 1 to Day 181 (study end)
- Number of Participants with AEs Leading to withdrawal from the studyTime frame: From Day 1 to Day 181 (study end)
- Number of Participants with any Laboratory abnormalitiesTime frame: Day 8 compared to Screening Visit (up to Day -14)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Norwood, South Australia, Australia
GSK Investigational Site
Camberwell, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.